Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Cerilliant
Express Scripts
Mallinckrodt
US Army
Covington
Farmers Insurance
Queensland Health
Teva

Generated: November 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020772

« Back to Dashboard

NDA 020772 describes SUCRAID, which is a drug marketed by Qol Medcl and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the SUCRAID profile page.

The generic ingredient in SUCRAID is sacrosidase. One supplier is listed for this compound. Additional details are available on the sacrosidase profile page.
Summary for 020772
Tradename:SUCRAID
Applicant:Qol Medcl
Ingredient:sacrosidase
Patents:1
Generic Entry Opportunity Date for 020772
Generic Entry Date for 020772*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 020772
Suppliers and Packaging for NDA: 020772
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SUCRAID sacrosidase SOLUTION;ORAL 020772 NDA QOL Medical, LLC 67871-111 67871-111-04 2 BOTTLE in 1 CARTON (67871-111-04) > 118 mL in 1 BOTTLE (67871-111-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;ORALStrength8,500 IU/ML
Approval Date:Apr 9, 1998TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Feb 7, 2034Product Flag?YSubstance Flag?YDelist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Cerilliant
Cantor Fitzgerald
Julphar
Healthtrust
Deloitte
Harvard Business School
Federal Trade Commission
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.